In line with the latter observations, Brunner and colleagues studied the role of IDH1 and IDH2 mutations in the response of AML patients to induction therapy and found no differences in CR rates, OS, and EFS between IDH-mutated and wild-type patients, nor a correlation between baseline 2-HG levels and remission rates [77]. Here, IDH2 is linked to acute myeloid leukemia.